Skip to main content
. 2024 Nov 4;37(1):5–15. doi: 10.1097/GCO.0000000000001002

FIGURE 1.

FIGURE 1

Overview of antibody–drug conjugates approved in gynecologic malignancies. Created with Biorender.com. ADC, antibody–drug conjugates; DAR, drug antibody ratio; MTi, microtubule inhibitor; Ti, topoisomerase inhibitor; FRα, folate receptor alpha; CLDN6, claudin-6; HER-2, human epidermal growth factor receptor 2; DM4, N20-deacetyl-N20-(4-mer-capto-4-methyl-1-oxopentyl)-maytansin; MMAE, monomethyl auristatin E.